You are here:

NICE
NICE Guidance
Conditions and diseases
Cancer
Head and neck cancers

Head and neck cancers Products

A list of all our products on head and neck cancers

Filter

Product type
1 selected

Product typeGuidanceQuality standardsShared learning

Guidance programme

Guidance programmeNICE guidelinesTechnology appraisal guidanceInterventional procedures guidance

Status

StatusPublishedIn developmentAwaiting development

New and updated
1 selected

New and updatedNew in the last 6 months

Showing 2 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 October 2023
Lenvatinib with pembrolizumab for untreated PD-L1-positive recurrent or metastatic squamous cell head and neck cancer TS ID 10502
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC